Literature DB >> 2145359

Regulation of human cytotoxic T lymphocyte development by IL-7.

C J Hickman1, J A Crim, H S Mostowski, J P Siegel.   

Abstract

The effects of IL-7 on the generation of human CTL in alloantigen-, virus-, and lectin-stimulated systems were examined. Addition of IL-7 at the onset of cultures resulted in marked (up to 80-fold) augmentation of cytotoxicity accompanied by smaller (1.5- to 4-fold) increases in total lymphocyte number. Studies of CTL development in purified lectin-stimulated CD8+ T cell populations demonstrated that IL-7 could act directly on the CD8+ lymphocyte subset to augment cytotoxicity. In MLC, the IL-7-induced enhancement of cytotoxicity was found to be mediated primarily by the CD8+ subpopulation of lymphocytes. Late addition of IL-7 (day 5 of 7) resulted in an increase in cytolytic activity that was associated with little or no increase in total or activated CD8+ lymphocyte number indicating that IL-7 may act as a differentiation factor for human CTL. A role for endogenous IL-7 in CTL development was suggested by the observation that addition of neutralizing antiserum to IL-7 to MLC at initiation (or 5 days thereafter) resulted in decreased levels of cytotoxicity. These results indicate that IL-7 can exert major up-regulatory effects on human CTL development and suggest that these effects are both proliferative and differentiative.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2145359

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Prime-boost vaccination with rBCG/rAd35 enhances CD8⁺ cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates.

Authors:  Sayma Rahman; Isabelle Magalhaes; Jubayer Rahman; Raija K Ahmed; Donata R Sizemore; Charles A Scanga; Frank Weichold; Frank Verreck; Ivanela Kondova; Jerry Sadoff; Rigmor Thorstensson; Mats Spångberg; Mattias Svensson; Jan Andersson; Markus Maeurer; Susanna Brighenti
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

2.  Interleukin-15 differentially enhances the expression of interferon-gamma and interleukin-4 in activated human (CD4+) T lymphocytes.

Authors:  P Borger; H F Kauffman; D S Postma; M T Esselink; E Vellenga
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

3.  IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).

Authors:  G Ferrari; K King; K Rathbun; C A Place; M V Packard; J A Bartlett; D P Bolognesi; K J Weinhold
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

4.  Stimulation of B-cell lymphopoiesis by interleukin-7 leads to aggravation of murine leishmaniasis.

Authors:  A Gessner; A Will; M Vieth; K Schröppel; M Röllinghoff
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

5.  Interleukin-7 is a growth factor for Sézary lymphoma cells.

Authors:  A Dalloul; L Laroche; M Bagot; M D Mossalayi; C Fourcade; D J Thacker; D E Hogge; H Merle-Béral; P Debré; C Schmitt
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

6.  Interleukin-7 enhances antimicrobial activity against Leishmania major in murine macrophages.

Authors:  A Gessner; M Vieth; A Will; K Schröppel; M Röllinghoff
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

7.  Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis.

Authors:  J A G van Roon; K A F M Glaudemans; J W J Bijlsma; F P J G Lafeber
Journal:  Ann Rheum Dis       Date:  2003-02       Impact factor: 19.103

8.  Interleukin-7 is a potent co-stimulus of the adhesion pathway involving CD2 and CD28 molecules.

Authors:  R Costello; H Brailly; F Mallet; C Mawas; D Olive
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

9.  Interleukin 7 induces CD4+ T cell-dependent tumor rejection.

Authors:  H Hock; M Dorsch; T Diamantstein; T Blankenstein
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

10.  Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.

Authors:  P Möller; Y Sun; T Dorbic; S Alijagic; A Makki; K Jurgovsky; M Schroff; B M Henz; B Wittig; D Schadendorf
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.